EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Therapeutic potential of co-signaling receptor modulation in hepatitis B

Francesco Andreata, Chiara Laura, Micol Ravà, Caroline C Krueger, Xenia Ficht, Keigo Kawashima, Cristian G Beccaria, Federica Moalli, Bianca Partini, Valeria Fumagalli, Giulia Nosetto, Pietro Di Lucia und 18 weitere

Cell · 2024-07 · 187 (15) · 4078-4094.e21

DOI: 10.1016/j.cell.2024.05.038 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cell, 2024-07. Verfasst von Francesco Andreata und 29 weiteren Autor:innen. Beteiligte Einrichtung: Division of Immunology, Transplantation, and Infectious Diseases, IRCCS San Raffaele Scientific Institute, Milan, Italy; Vita-Salute San Raffaele Uni…. Hauptthemen laut MEDLINE: CD8-Positive T-Lymphocytes, Hepatitis B, Chronic, Hepatitis B virus. Die Arbeit wurde bisher 58-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Associazione Italiana per la Ricerca sul Cancro, European Research Council, Ministero dell'Istruzione dell'Universita e della Ricerca.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Reversing CD8+ T cell dysfunction is crucial in treating chronic hepatitis B virus (HBV) infection, yet specific molecular targets remain unclear. Our study analyzed co-signaling receptors during hepatocellular priming and traced the trajectory and fate of dysfunctional HBV-specific CD8+ T cells. Early on, these cells upregulate PD-1, CTLA-4, LAG-3, OX40, 4-1BB, and ICOS. While blocking co-inhibitory receptors had minimal effect, activating 4-1BB and OX40 converted them into antiviral effectors. Prolonged stimulation led to a self-renewing, long-lived, heterogeneous population with a unique transcriptional profile. This includes dysfunctional progenitor/stem-like (TSL) cells and two distinct dysfunctional tissue-resident memory (TRM) populations. While 4-1BB expression is ubiquitously maintained, OX40 expression is limited to TSL. In chronic settings, only 4-1BB stimulation conferred antiviral activity. In HBeAg+ chronic patients, 4-1BB activation showed the highest potential to rejuvenate dysfunctional CD8+ T cells. Targeting all dysfunctional T cells, rather than only stem-like precursors, holds promise for treating chronic HBV infection.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CD8-Positive T-LymphocytesHepatitis B, ChronicHepatitis B virusHumansTumor Necrosis Factor Receptor Superfamily, Member 9Signal TransductionAnimalsReceptors, OX40MiceProgrammed Cell Death 1 ReceptorAntigens, CD

Stichwörter der Autor:innen

4-1BBCD8(+) T cellsOX40T cell dysfunctionchronic viral infectionhepatitis B virusimmunotherapyliver

Substanzen

Tumor Necrosis Factor Receptor Superfamily, Member 9Receptors, OX40Programmed Cell Death 1 ReceptorAntigens, CD

Autor:innen und Institutionen

  • Division of Immunology, Transplantation, and Infectious Diseases, IRCCS San Raffaele Scientific Institute, Milan, Italy; Vita-Salute San Raffaele University, Milan, Italy.
  • Division of Immunology, Transplantation, and Infectious Diseases, IRCCS San Raffaele Scientific Institute, Milan, Italy; Vita-Salute San Raffaele University, Milan, Italy; Center for Omics Sciences, IRCCS San Raffaele S…
  • Division of Immunology, Transplantation, and Infectious Diseases, IRCCS San Raffaele Scientific Institute, Milan, Italy.
  • Laboratory of Viral Immunopathology, Unit of Infectious Diseases and Hepatology, Azienda Ospedaliero-Universitaria di Parma, Parma, Italy.
  • Division of Immunology, Transplantation, and Infectious Diseases, IRCCS San Raffaele Scientific Institute, Milan, Italy; Center for Omics Sciences, IRCCS San Raffaele Scientific Institute, Milan, Italy.
  • San Raffaele-Telethon Institute for Gene Therapy (SR-Tiget), Milan, Italy.

Förderung

  • Associazione Italiana per la Ricerca sul Cancro
  • European Research Council
  • Ministero dell'Istruzione dell'Universita e della Ricerca
  • Fondazione Cariplo
  • Allos Therapeutics
  • Vir Biotechnology
  • European Molecular Biology Organization
  • Japan Agency for Medical Research and Development

Zitieren

APA

Andreata, F., Laura, C., Ravà, M., Krueger, C. C., Ficht, X., Kawashima, K., Beccaria, C. G., Moalli, F., Partini, B., Fumagalli, V., Nosetto, G., Di Lucia, P., Montali, I., Garcia-Manteiga, J. M., Bono, E. B., Giustini, L., Perucchini, C., Venzin, V., Ranucci, S., …, & Iannacone, M. (2024). Therapeutic potential of co-signaling receptor modulation in hepatitis B. Cell, 187(15), 4078-4094.e21. https://doi.org/10.1016/j.cell.2024.05.038

Vancouver

Andreata F, Laura C, Ravà M, Krueger CC, Ficht X, Kawashima K, et al. Therapeutic potential of co-signaling receptor modulation in hepatitis B. Cell. 2024;187(15):4078-4094.e21. doi:10.1016/j.cell.2024.05.038

BibTeX
@article{Andreata2024,
  author = {Andreata, Francesco and Laura, Chiara and Ravà, Micol and Krueger, Caroline C and Ficht, Xenia and Kawashima, Keigo and Beccaria, Cristian G and Moalli, Federica and Partini, Bianca and Fumagalli, Valeria and Nosetto, Giulia and Di Lucia, Pietro and Montali, Ilaria and Garcia-Manteiga, José M and Bono, Elisa B and Giustini, Leonardo and Perucchini, Chiara and Venzin, Valentina and Ranucci, Serena and Inverso, Donato and De Giovanni, Marco and Genua, Marco and Ostuni, Renato and Lugli, Enrico and Isogawa, Masanori and Ferrari, Carlo and Boni, Carolina and Fisicaro, Paola and Guidotti, Luca G and Iannacone, Matteo},
  title = {Therapeutic potential of co-signaling receptor modulation in hepatitis B},
  journal = {Cell},
  year = {2024},
  volume = {187},
  number = {15},
  pages = {4078--4094.e21},
  doi = {10.1016/j.cell.2024.05.038}
}
Kostenlos starten →